Published July 2020 (CAT No: VAMV085)
****This product is a summary presentation (.pdf), 1 x forecast models (.xls)
Contents – Summary presentation (.pdf)1
[SECTION 1] Rift Valley Fever vaccines: key model outputs
[SECTION 2] Rift Valley Fever: disease background and epidemiology
[SECTION 3] Rift Valley Fever vaccines: R&D pipeline and competitor activity
[SECTION 4] Rift Valley Fever vaccines: modelling commercial potential
About VacZine Analytics
PAGES: >120 slides fully referenced/sourced. Available in .pdf form
Contents – 1 x vaccine demand models (MS Excel-based)
Worksheets = >100 interconnected
|【英語タイトル】MarketVIEW: Rift Valley Fever vaccines - Global vaccine commercial opportunity assessment, global market forecast|
・レポート形式：Executive presentation (>120 slides.pdf) + 1 x MS-Excel
forecast model(s) (.xls)
|Region Price||USD6,995 ⇒換算￥748,465||見積依頼/購入/質問フォーム|
Rift Valley Fever (RVF) is an acute zoonotic disease affecting domestic and wild ruminants and can cause moderate-to-severe illness in humans. It is caused by Rift Valley Fever Virus (RVFV), a negative single-stranded RNA arbovirus of the family Bunyaviridae (genus Phlebovirus). The main route of infection in humans is via contact with tissues and bodily fluids or consumption of raw milk from infected livestock. Mosquitos can also transmit the virus to both animals and humans. To date no human-to-human transmission has been documented.
Rift Valley Fever has mainly affected Sub-saharan Africa with major outbreaks in Kenya (1997-98), Somalia and Tanzania. More recent outbreaks have occurred in Saudi Arabia and Yemen (2000-2001). It is estimated that between 1997-2010 more than 500,000 cases of RVF occurred with over 2,000 deaths reported. A main concern is that more RVF outbreaks could occur due to the existence of competent vectors in non-endemic areas. RVF can also cause significant economic damage and famine to areas reliant on livestock rearing and food trading.
Rift Valley Fever Virus has been designated a priority pathogen by the Coalition of Epidemic Preparedness Innovations (CEPI) and the World Health Organisation. An inactivated vaccine has been developed for human use (Special Immunization Program) but its profile is not suitable (or licensed) for large scale deployment.
This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>120 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a Rift Valley Fever vaccine (human) to 2040. The model (34 countries)* covers ‘at risk’ populations or identified target segments in both the public and private sector (based on latest disease understanding). A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *Some are rolled up, Photo credit: Jonas Nordberg/Unsplash
THIS PRODUCT IS A SUMMARY PRESENTATION (>120 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)